go-v.orgdoi

Chloroquine enjoys a renaissance as an antineoplastic therapy

Virginia A. Espina, Lance A. Liotta · Clinical Investigation · 2013

  • DOI 10.4155/cli.13.58
  • Publisher OMICS Publishing Group
  • Type article
  • Issued 2013

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

Clinical Investigation · OMICS Publishing Group · article · 2013

Abstract

Chloroquine (CQ) and hydroxychloroquine (HCQ), oral lysosomotropic agents with well-studied toxicity profiles, and antimalarial and antirheumatic activity, have been repurposed as antineoplastic agents based on preclinical data showing efficacy in preinvasive cancer, cancer stem cells and metastatic cancer. Phase I/II clinical trials are providing safety and efficacy data regarding CQ or HCQ monotherapy or combination therapy with molecularly targeted inhibitors in patients diagnosed with glioblastoma multiforme, breast ductal carcinoma in situ, non-small-cell lung cancer, hepatocellular, pancreatic, or renal cancer, multiple myeloma, or chronic lymphocytic leukemia.

Disruption of autophagy-mediated cell survival is a major therapeutic rationale for using CQ and HCQ. CQ and HCQ are the first agents that rationally target cytoprotective autophagy in cancer. Short-term treatment of preinvasive breast cancer with CQ introduces the concept of preventing invasive cancer by killing preinvasive lesions.

Open the resolved locator · 10.4155/cli.13.58

Metadata licence: OpenAlex metadata (CC0)

Registry
OpenAlex DOI index + API
Fetched
2026-11-20 01:37 UTC
Cache state
not cached yet (bulk-index+openalex)
Locator
https://doi.org/10.4155/cli.13.58
Metadata licence
OpenAlex metadata (CC0)
Scope
Metadata as returned by the resolver; abstracts are never generated here.